Hualan Biological Engineering Inc. (SHE:002007)

Market Cap	23.39B -20.6%
Revenue (ttm)	4.49B +0.7%
Net Income	857.61M -24.7%
EPS	0.47 -24.6%
Shares Out	1.83B
PE Ratio	27.26
Forward PE	23.27
Dividend	1.00 (7.92%)
Ex-Dividend Date	Jun 15, 2026

Volume	13,069,552
Open	12.79
Previous Close	12.63
Day's Range	12.42 - 12.96
52-Week Range	11.72 - 18.39
Beta	0.36
Analysts	Strong Buy
Price Target	18.04 (+40.94%)
Earnings Date	Aug 29, 2026

About SHE:002007

Hualan Biological Engineering Inc., together with its subsidiaries, engages in the research, development, production, and sale of biological products in China and internationally. The company offers blood products, including human serum albumin, human prothrombin complex concentrate, human coagulation factor VIII, human fibrinogen, and freeze-dried human fibrin glue for surgical use, as well as intravenous, human, rabies, hepatitis B, and tetanus immunoglobulin for various therapeutic applications. It also provides vaccine products, such as inf...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 4,117
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002007

Financial Performance

In 2025, SHE:002007's revenue was 4.60 billion, an increase of 4.93% compared to the previous year's 4.38 billion. Earnings were 940.40 million, a decrease of -13.55%.

Analyst Summary

According to 7 analysts, the average rating for 002007 stock is "Strong Buy." The 12-month stock price target is ¥18.04, which is an increase of 40.94% from the latest price.

Price Target

¥18.04

(40.94% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 10, 2026

Data Sources Report a data error